Previous 10 | Next 10 |
-- Fiscal 2019 Revenues Increase 114% over Fiscal 2018 to $54.4M-- -- Continued Strength in Synthetic Biology and NGS Businesses – -- Expect FY 2020 Revenues of $80M to $84M – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an expanded antibody optimization collaboration with Pandion Therapeutics. Based on the successful completion of ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fourth quarter and fiscal year ended September 30, 2019, followi...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Patrick J. Finn, Ph.D., to the newly-created position of chief commercial officer. Dr. Finn prev...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, wi...
First-in-class software platform digitalizes Twist Biopharma’s innovative antibody lead identification and optimization Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Twist Biopharma, a division of Twist Biosc...
The following healthcare companies have filed for mixed shelf offerings: More news on: Cytokinetics, Incorporated, Twist Bioscience Corporation, Axonics Modulation Technologies, Inc., Healthcare stocks news, Read more ...
-- Companies Combine Best-in-Class Product Lines for Next-Generation Sequencing -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MGI International Sales Co., Limite...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Nicolas M. Barthelemy to its board of directors. Mr. Barthelemy brings extensive experience, b...
-- Consortium Developed an Integrated Solution for Better Preparedness and Faster Response to Outbreaks and Epidemics in High-Risk Areas -- The Praesens Foundation, the Institut Pasteur, the Institut Pasteur de Dakar, University of Nebraska Medical Center and Twist Bioscience Corporati...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...